Cargando…

Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride

BACKGROUND/AIMS: Cystinosis is a rare, autosomal recessive disorder causing defective transport of cystine out of lysosomes. Cystadrops (0.55% cysteamine hydrochloride in viscous solution) has been used on a named-patient basis to treat the accumulation of cystine crystals in the cornea in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hong, Labbé, Antoine, Baudouin, Christophe, Plisson, Celine, Giordano, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077218/ https://www.ncbi.nlm.nih.gov/pubmed/32593979 http://dx.doi.org/10.1136/bjophthalmol-2020-316450

Ejemplares similares

Effects of long-term cysteamine treatment in patients with cystinosis
por: Ariceta, Gema, et al.
Publicado: (2017)

Analysis of tear film in cystinosis patients treated with topical viscous cysteamine hydrochloride (Cystadrops(®))
por: Sergio, Petroni, et al.
Publicado: (2022)

Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023)

Feasibility of cardiac MR thermometry at 0.55 T
por: Mooiweer, Ronald, et al.
Publicado: (2023)

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)

Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
por: Linden, Simone, et al.
Publicado: (2020)

Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review
por: Makuloluwa, Achini K, et al.
Publicado: (2018)

Lung parenchyma transverse relaxation rates at 0.55 T
por: Li, Bochao, et al.
Publicado: (2022)

Low-field 0.55 T MRI evaluation of the fetus
por: Ponrartana, Skorn, et al.
Publicado: (2023)

Real-time MRI of the moving wrist at 0.55 tesla
por: Chaudhari, Abhijit J, et al.
Publicado: (2023)

Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
por: Jamalpoor, Amer, et al.
Publicado: (2021)

Importance of adherence to topical cysteamine in infantile ocular cystinosis: An illustrative case
por: Bayram-Suverza, Mauricio, et al.
Publicado: (2022)

Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023)

A comparison of cine CMR imaging at 0.55 T and 1.5 T
por: Bandettini, W. Patricia, et al.
Publicado: (2020)

In vivo confocal microscopy and anterior segment optical coherence tomography follow-up of cysteamine treatment in corneal cystinosis
por: Ozdemir, Huseyin Baran, et al.
Publicado: (2019)

A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
por: van Stein, Christina, et al.
Publicado: (2021)

A new proof of evidence of cysteamine quantification for therapeutic drug monitoring in patients with cystinosis
por: Franzin, Martina, et al.
Publicado: (2022)

A monoclinic polymorph of cysteamine hydrochloride
por: Ahmad, Saeed, et al.
Publicado: (2009)

High-Performance 0.55-T Lung MRI in a Patient with COVID-19 Infection
por: Campbell-Washburn, Adrienne E., et al.
Publicado: (2021)

Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults
por: Ariceta, Gema, et al.
Publicado: (2015)

Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives
por: Castro-Balado, Ana, et al.
Publicado: (2020)

Response to Cysteamine in Osteoclasts Obtained from Patients with Nephropathic Cystinosis: A Genotype/Phenotype Correlation
por: Quinaux, Thomas, et al.
Publicado: (2021)

Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014)

Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis
por: Peeters, Freya, et al.
Publicado: (2019)

Contrast‐optimal simultaneous multi‐slice bSSFP cine cardiac imaging at 0.55 T
por: Tian, Ye, et al.
Publicado: (2022)

Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine
por: De Leo, Ester, et al.
Publicado: (2022)

Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom
por: Lashilola, Seun, et al.
Publicado: (2023)

Superconductivity with twofold symmetry in Bi(2)Te(3)/FeTe(0.55)Se(0.45) heterostructures
por: Chen, Mingyang, et al.
Publicado: (2018)

Spatially dispersing Yu-Shiba-Rusinov states in the unconventional superconductor FeTe(0.55)Se(0.45)
por: Chatzopoulos, Damianos, et al.
Publicado: (2021)

High regularity of Z-DNA revealed by ultra high-resolution crystal structure at 0.55 Å(†)
por: Brzezinski, Krzysztof, et al.
Publicado: (2011)

Ökonomische Aspekte der Niederfeld-Magnetresonanztomographie: Anschaffung, Installation und Unterhaltskosten von 0,55 T-Geräten
por: Vosshenrich, Jan, et al.
Publicado: (2022)

Prospective Assessment of Cerebral Microbleeds with Low-Field Magnetic Resonance Imaging (0.55 Tesla MRI)
por: Rusche, Thilo, et al.
Publicado: (2023)

A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
por: Berends, Cécile L., et al.
Publicado: (2021)

Anisotropic structure of the order parameter in FeSe(0.45)Te(0.55) revealed by angle-resolved specific heat
por: Zeng, B., et al.
Publicado: (2010)

Native contrast visualization and tissue characterization of myocardial radiofrequency ablation and acetic acid chemoablation lesions at 0.55 T
por: Kolandaivelu, Aravindan, et al.
Publicado: (2021)

Imaging gravity-induced lung water redistribution with automated inline processing at 0.55 T cardiovascular magnetic resonance
por: Seemann, Felicia, et al.
Publicado: (2022)

Thermoelectric Performance of Single-Phase Tellurium-Reduced Quaternary (PbTe)(0.55)(PbS)(0.1)(PbSe)(0.35)
por: Shaabani, Laaya, et al.
Publicado: (2019)

Discrete energy levels of Caroli-de Gennes-Matricon states in quantum limit in FeTe(0.55)Se(0.45)
por: Chen, Mingyang, et al.
Publicado: (2018)

The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series
por: Biswas, Susmito, et al.
Publicado: (2018)

The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study
por: Bjerre, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bumknboocq65q4t48mkscck7ri